Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.41 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.37 |
| ▸ | ITK | Q08881 | 4/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693414 | 1.00 | BTK (0.41) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693472 | 0.88 | BTK (0.46) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693470 | 0.88 | BTK (0.46) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693422 | 0.85 | BTK (0.53) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693423 | 0.85 | BTK (0.53) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693576 | 0.85 | SRC (0.46) | BTKEGFRLCKITKKDR | |
| SCHEMBL14693575 | 0.85 | SRC (0.46) | BTKEGFRLCKITKKDR | |
| SCHEMBL14693516 | 0.80 | FGFR1 (0.41) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693517 | 0.80 | FGFR1 (0.41) | BTKEGFRLCKITKFGFR2 | |
| SCHEMBL14693479 | 0.76 | BTK (0.50) | BTKEGFRLCKITKFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | BTK 1/4885EGFR 1715/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.